[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors]

Ugeskr Laeger. 2007 Sep 10;169(37):3085-7.
[Article in Danish]

Abstract

This review addresses molecular targeted therapies for metastatic breast cancer. As the complex cellular aberrations inherent to cancer cells continue to be revealed, new therapies to target specific cellular pathways are being developed, and several are currently in clinical trials. The most promising of these new agents are discussed focusing on monoclonal antibodies and tyrosine kinase inhibitors to human epidermal growth factor receptors (HER) and vascular endothelial growth factor (VEGF).

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / secondary
  • ErbB Receptors / drug effects
  • ErbB Receptors / metabolism
  • Erlotinib Hydrochloride
  • Female
  • Gefitinib
  • Humans
  • Lapatinib
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / administration & dosage
  • Quinazolines / therapeutic use
  • Receptors, Vascular Endothelial Growth Factor / drug effects
  • Receptors, Vascular Endothelial Growth Factor / metabolism
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • Lapatinib
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Receptors, Vascular Endothelial Growth Factor
  • pertuzumab
  • Trastuzumab
  • Gefitinib